These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2822645)

  • 1. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE; Johnston JL; Archer GL
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of LY146032 against gram-positive bacteria.
    Silva M; Jacobus NV; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH; Maher LA; Redding JS
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
    Stratton CW; Liu C; Weeks LS
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F; Neu HC
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.
    Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1986 Dec; 30(6):938-9. PubMed ID: 3028254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.
    Urban C; Mariano N; Mosinka-Snipas K; Wadee C; Chahrour T; Rahal JJ
    J Antimicrob Chemother; 1996 Feb; 37(2):361-4. PubMed ID: 8707748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LY146032: activity and resistance development in vitro.
    Mouton RP; Mulders SL
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.
    Bush LM; Boscia JA; Wendeler M; Pitsakis PG; Kaye D
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1198-200. PubMed ID: 2552901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.